Methylphenylsulfone

Methylphenylsulfone

SCHEMBL561404

CS(=O)(=O)c1ccccc1.OBO

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.54
ENPP2 Q13822 2/20 0.52
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HTR6 P50406 1/20 0.48
PSIP1 O75475 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
AKR1C3 P42330 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylphenylsulfone SCHEMBL78253 0.89 PTGS2 (0.62) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL1332357 0.89 PTGS2 (0.62) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL5499087 0.87 PTGS2 (0.60) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL28288198 0.84 PTGS2 (0.58) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL28158010 0.84 PTGS2 (0.58) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL28046614 0.84 PTGS2 (0.58) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL28097901 0.84 PTGS2 (0.58) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL25293256 0.83 PTGS2 (0.52) PTGS2ENPP2TSHRSMN1; SMN2HTR6
Methylphenylsulfone SCHEMBL11042562 0.83 PTGS2 (0.52) PTGS2ENPP2TSHRSMN1; SMN2AKR1C2
Methylphenylsulfone SCHEMBL28291817 0.83 ENPP2 (0.70) PTGS2ENPP2TSHRSMN1; SMN2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109134492-B Thienopyrimidone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 中国科学院广州生物医药与健康研究院 2021-08-13 CN disclosed
EP-2970230-B1 SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C BOEHRINGER INGELHEIM INT (DE) 2019-05-22 EP disclosed
US-9302985-B2 Benzyl sulfonamide derivatives as RORc modulators GENENTECH, INC. (US) 2016-04-05 US disclosed
EP-2970230-A1 SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C Boehringer Ingelheim International GmbH (DE) 2016-01-20 EP disclosed
EP-2928863-A1 BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS F. Hoffmann-La Roche AG (CH) 2015-10-14 EP disclosed
US-8889708-B2 Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 US disclosed
WO-2014140081-A1 SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-18 WO disclosed
US-20140275155-A1 SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-18 US disclosed
WO-2014090710-A1 BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2014-06-19 WO disclosed
US-20140163110-A1 BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS GENENTECH, INC. (US) 2014-06-12 US disclosed
EP-1782810-A2 Selective estrogen receptor modulators containing a phenylsulfonyl group Eli Lilly & Company (US) 2007-05-09 EP disclosed
EP-1735278-A1 HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-12-27 EP disclosed
US-20060183736-A1 Selective estrogen receptor modulators containing a phenylsulfonyl group ELILILLY AND COMPANY 2006-08-17 US disclosed
WO-2006073610-A2 NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-07-13 WO disclosed
US-20060128729-A1 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-06-15 US disclosed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO disclosed
WO-2006019833-A1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-02-23 WO disclosed
WO-2005097740-A1 HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-10-20 WO disclosed
EP-1530470-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP ELI LILLY AND COMPANY (US) 2005-05-18 EP disclosed
WO-2004009086-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP ELI LILLY AND COMPANY (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163110-A1 BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS RORC, RORA, RORB PTGS2 2414/4885ENPP2 1891/4885TSHR 159/4885
US-20060183736-A1 Selective estrogen receptor modulators containing a phenylsulfonyl group GPER1, ESR2, ESR1 PTGS2 192/4885ENPP2 1066/4885TSHR 1047/4885
US-20140275155-A1 SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C CTSC, CPN1, CPA1 PTGS2 2961/4885ENPP2 1485/4885TSHR 4273/4885
US-20060128729-A1 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them HPSE, ENGASE, UGCG PTGS2 334/4885ENPP2 123/4885TSHR 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.